famotidine has been researched along with Carcinoma, Non-Small Cell Lung in 1 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mori, K | 1 |
| Tominaga, K | 1 |
| Yokoyama, K | 1 |
| Suga, Y | 1 |
| Kishiro, I | 1 |
| Tsurui, M | 1 |
1 trial available for famotidine and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Efficacy of famotidine in patients with acute gastric mucosal injury after continuous infusion of cisplatin plus vindesine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Flow Velocity; Carcinoma, Non-Sma | 1995 |